Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WU 409: Immune Responses to Rabies Vaccine
NCT07399951Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2023
- Primary completion
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rabies virus inactivated antigen, B, Rabies vaccine and rabies immune globulin (human) in rabies (3 arms), sponsored by Washington University School of Medicine. Started Oct 2023; status: completed.
02
Drugs
rabies virus inactivated antigen, BRabies vaccinerabies immune globulin (human)
03
Conditions
rabies
Beyond the preview
Go deeper on NCT07399951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07399951.